Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Novel Immune Cell-Based Therapies to Eradicate High-Risk Acute Myeloid Leukemia.

Frontiers in immunology - 1 Jan 2021

Limongello Roberto, Marra Andrea, Mancusi Antonella, Bonato Samanta, Hoxha Eni, Ruggeri Loredana, Hui Susanta, Velardi Andrea, Pierini Antonio

Abstract excerpt

Adverse genetic risk acute myeloid leukemia (AML) includes a wide range of clinical-pathological entities with extremely poor outcomes; thus, novel therapeutic approaches are needed. Promising results achieved by engineered chimeric antigen receptor (CAR) T cells in other blood neoplasms have paved the way for the development of immune cell-based therapies for adverse genetic risk AML. Among these, adoptive cell...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Diffusion of Innovation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunotherapy, Adoptive

Share to Killer Cells, Natural

Share to Leukemia, Myeloid, Acute

Share to Receptors, Chimeric Antigen

Share to Risk Assessment

Share to T-Lymphocytes

Source

Open in PubMed Open full text

Identifiers

PMID: 34413848
DOI: 10.3389/fimmu.2021.695051
PMCID: PMC8368440

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Novel Immune Cell-Based Therapies to Eradicate High-Risk Acute Myeloid Leukemia.PMID 34413848Read ↗

Precision Medicine Approaches in Acute Myeloid Leukemia with Adverse GeneticsSemantic proximity Read ↗

The Black Hole: CAR T Cell Therapy in AMLSemantic proximity Read ↗

The Black Hole: CAR T cell Therapy in AMLSemantic proximity Read ↗

Advances in therapeutic options for newly diagnosed, high-risk AML patientsSemantic proximity Read ↗

Precision Medicine Approaches in Acute Myeloid Leukemia with Adverse GeneticsSemantic proximity Read ↗

High percentage of bone marrow CD8+ tissue-resident-like T cells predicts inferior survival in patients with acute myeloid leukemiaSemantic proximity Read ↗

Development of a poor-prognostic-mutations derived immune prognostic model for acute myeloid leukemia.Semantic proximity Read ↗

The interaction between common genetic mutations in AML and the immune landscape: mechanisms and implications for immune responseSemantic proximity Read ↗

Optimization of universal allogeneic CAR-T cells combining CRISPR and transposon-based technologies for treatment of acute myeloid leukemiaSemantic proximity Read ↗

Identification of molecular and cytogenetic risk factors for unfavorable core-binding factor-positive adult AML with post-remission treatment outcome analysis including transplantation.Semantic proximity Read ↗

CD8+T cells expressing both PD-1 and TIGIT but not CD226 are dysfunctional in acute myeloid leukemia (AML) patients.Semantic proximity Read ↗

Adoptive NK cell therapy in AML: progress and challengesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.